Targeting Cancer-Related Inflammation: Chinese Herbal Medicine Inhibits Epithelial-to-Mesenchymal Transition in Pancreatic Cancer

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Zhang, Juan ^a,b,c   Wang, Peng ^a,b   Ouyang, Huaqiang ^a,b   Yin, Jianhua ^a,b   Liu, Aihua ^c   Ma, Chunzheng ^c   Liu, Luming ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c HENAN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; CHINESE DRUG; INTERLEUKIN 6; INTERLEUKIN 8; NERVE CELL ADHESION MOLECULE; TRANSCRIPTION FACTOR SLUG; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INFILTRATION; CANCER INHIBITION; CELL MIGRATION; CHINESE MEDICINE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HERBAL MEDICINE; HUMANS; INFLAMMATION; INTERLEUKIN-6; LIVER NEOPLASMS; MICE; MODELS, BIOLOGICAL; PANCREATIC NEOPLASMS; TUMOR BURDEN;

EID: 84880788280     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070334     Document Type: Article

References (46)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA, (2006) Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20: 1218-1249.
3. Liu E, Xiang Y, Jin F, Zhou S, Sun L, et al. (2004) Cancer incidence trends in urban Shanghai,1972-1999. Tumor 24: 11-15.
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966.
5. Thiery JP, Acloque H, Huang RY, Nieto MA, (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
6. von Burstin J, Eser S, Paul MC, Seidler B, Brandl M,et al. (2009) E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 137: 361-371, 371 e361-365.
7. Javle MM, Gibbs JF, Iwata KK, Pak Y, Rutledge P, et al. (2007) Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol 14: 3527-3533.
8. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, et al. (2009) Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69: 2400-2407.
9. Sun Y, Xun K, Wang Y, Chen X, (2009) A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs. Anticancer Drugs 20: 757-769.
10. Dong P, Zhang Y, Gu J, Wu W, Li M, et al. (2011) Wogonin, an active ingredient of Chinese herb medicine Scutellaria baicalensis, inhibits the mobility and invasion of human gallbladder carcinoma GBC-SD cells by inducing the expression of maspin. J Ethnopharmacol 137: 1373-1380.
11. Belguise K, Guo S, Yang S, Rogers AE, Seldin DC, et al. (2007) Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, slug, and an invasive phenotype. Cancer Res 67: 11742-11750.
12. Tsai CH, Lin FM, Yang YC, Lee MT, Cha TL, et al. (2009) Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin Cancer Res 15: 5435-5444.
13. Xiong W, Ren ZG, Qiu SJ, Sun HC, Wang L, et al. (2010) Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin. BMC Cancer 10: 219.
14. Wang P, Chen Z, Meng ZQ, Luo JM, Lin JH, et al. (2010) Ski acts as therapeutic target of qingyihuaji formula in the treatment of SW1990 pancreatic cancer. Integr Cancer Ther 9: 50-58.
15. Yin JH, Shi WD, Zhu XY, Chen Z, Liu LM, (2012) Qingyihuaji formula inhibits progress of liver metastases from advanced pancreatic cancer xenograft by targeting to decrease expression of Cyr61 and VEGF. Integr Cancer Ther 11: 37-47.
16. Chen Z, Chen LY, Wang P, Dai HY, Gao S, et al. (2012) Tumor Microenvironment Varies under Different TCM ZHENG Models and Correlates with Treatment Response to Herbal Medicine. Evid Based Complement Alternat Med 2012: 635702.
17. Ouyang H, Wang P, Meng Z, Chen Z, Yu E, et al. (2011) Multimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or Chinese herbal medicine. Pancreas 40: 120-125.
18. Shi WD, Meng ZQ, Chen Z, Lin JH, Zhou ZH, et al. (2009) Identification of liver metastasis-related genes in a novel human pancreatic carcinoma cell model by microarray analysis. Cancer Lett 283: 84-91.
19. Wang P, Chen Z, Meng ZQ, Fan J, Luo JM, et al. (2009) Dual role of Ski in pancreatic cancer cells: tumor-promoting versus metastasis-suppressive function. Carcinogenesis 30: 1497-1506.
20. Wang P (2013) Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene doi:10.1038/onc.2012.598.
21. Graeser R, Bornmann C, Esser N, Ziroli V, Jantscheff P, et al. (2009) Antimetastatic effects of liposomal gemcitabine and empty liposomes in an orthotopic mouse model of pancreatic cancer. Pancreas 38: 330-337.
22. Bouvet M, Yang M, Nardin S, Wang X, Jiang P, et al. (2000) Chronologically-specific metastatic targeting of human pancreatic tumors in orthotopic models. Clin Exp Metastasis 18: 213-218.
23. Balkwill F, Charles KA, Mantovani A, (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217.
24. Mantovani A, Allavena P, Sica A, Balkwill F, (2008) Cancer-related inflammation. Nature 454: 436-444.
25. Yadav A, Kumar B, Datta J, Teknos TN, Kumar P, (2011) IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res 9: 1658-1667.
26. Huang C, Yang G, Jiang T, Zhu G, Li H, et al. (2011) The effects and mechanisms of blockage of STAT3 signaling pathway on IL-6 inducing EMT in human pancreatic cancer cells in vitro. Neoplasma 58: 396-405.
27. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, et al. (2009) Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28: 2940-2947.
28. Li CW, Xia W, Huo L, Lim SO, Wu Y, et al. (2012) Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res 72: 1290-1300.
29. Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C, (2011) IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res 71: 5296-5306.
30. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, et al. (2007) Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67: 10019-10026.
31. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L, (1992) The origin and function of tumor-associated macrophages. Immunol Today 13: 265-270.
32. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A, (2006) Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25: 315-322.
33. Steidl C, Lee T, Shah SP, Farinha P, Han G, et al. (2010) Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362: 875-885.
34. Chen Z, Gu K, Zheng Y, Zheng W, Lu W, et al. (2008) The use of complementary and alternative medicine among Chinese women with breast cancer. J Altern Complement Med 14: 1049-1055.
35. Chang KH, Brodie R, Choong MA, Sweeney KJ, Kerin MJ, (2011) Complementary and alternative medicine use in oncology: a questionnaire survey of patients and health care professionals. BMC Cancer 11: 196.
36. McCulloch M, See C, Shu XJ, Broffman M, Kramer A, et al. (2006) Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol 24: 419-430.
37. Lam W, Bussom S, Guan F, Jiang Z, Zhang W, et al. (2010) The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med 2: 45ra59.
38. Zhen T, Wu CF, Liu P, Wu HY, Zhou GB, et al. (2012) Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein. Sci Transl Med 4: 127ra138.
39. Wang L, Zhou GB, Liu P, Song JH, Liang Y, et al. (2008) Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A 105: 4826-4831.
40. Mantovani A, Sica A, (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22: 231-237.
41. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R, (2004) Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 101: 2727-2736.
42. Peinado H, Olmeda D, Cano A, (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7: 415-428.
43. Helle M, Boeije L, Pascual-Salcedo D, Aarden L, (1991) Differential induction of interleukin-6 production by monocytes, endothelial cells and smooth muscle cells. Prog Clin Biol Res 367: 61-71.
44. Kim DK, Oh SY, Kwon HC, Lee S, Kwon KA, et al. (2009) Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 9: 155.
45. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, et al. (2011) Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19: 456-469.
46. Tawara K, Oxford JT, Jorcyk CL, (2011) Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res 3: 177-189.